The effect of amlodipine besylate, losartan potassium, olmesartan medoxomil, and other antihypertensives on central aortic blood pressure and biomarkers of vascular function

Therapeutic Advances in Cardiovascular Disease

Volumn 5, Issue 5, 2011, Pages 241-273

  Khan, Bobby V ^a  

^a Atlanta Vascular Research Foundation   (United States)

Author keywords

amlodipine; biomarker; hypertension; losartan; olmesartan medoxomil; vascular cardiovascular dysfunction risk

Indexed keywords

ADIPONECTIN; AMLODIPINE; AMLODIPINE BESYLATE; AMLODIPINE PLUS OLMESARTAN; AMLODIPINE PLUS PERINDOPRIL; ANTIHYPERTENSIVE AGENT; ATENOLOL; AZELNIDIPINE; AZELNIDIPINE PLUS OLMESARTAN; BIOLOGICAL MARKER; BISOPROLOL; C REACTIVE PROTEIN; CYSTATIN C; ENALAPRIL; FOSINOPRIL PLUS HYDROCHLOROTHIAZIDE; GLUCOSE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; INDAPAMIDE; INTERLEUKIN 6; LISINOPRIL; LOSARTAN; LOSARTAN POTASSIUM; OLMESARTAN; PROCOLLAGEN; THIAZIDE DIURETIC AGENT; TRICHLORMETHIAZIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADD ON THERAPY; ANTIHYPERTENSIVE THERAPY; AORTA; BLOOD PRESSURE; CARDIOVASCULAR FUNCTION; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SYSTOLIC BLOOD PRESSURE;

AMLODIPINE; ANIMALS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; IMIDAZOLES; LOSARTAN; REPRODUCIBILITY OF RESULTS; TETRAZOLES;

EID: 80053066595     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944711420464     Document Type: Review

References (112)

1. Abramson J.L. Weintraub W.S. Vaccarino V. (2002) Association between pulse pressure and C-reactive protein among apparently healthy US adults. Hypertension 39: 197–202.
2. Aksnes T.A. Seljeflot I. Torjesen P.A. Hoieggen A. Moan A. Kjeldsen S.E. (2007) Improved insulin sensitivity by the angiotensin II-receptor blocker losartan is not explained by adipokines inflammatory markers, or whole blood viscosity. Metab Clin Exper 56: 1470–1477.
3. Albayrak S. Ordu S. Ozhan H. Yazici M. Aydin M. Alemdar R. et al (2009) Effect of olmesartan medoxomil on cystatin C level, left ventricular hypertrophy and diastolic function. Blood Press 18: 187–191.
4. Argani H. Ghorbanihaghjo A. Aghaeishahsavari M. Noroozianavval M. Rashtchizadeh N. Veisi P. et al (2008) Effects of losartan and enalapril on high-sensitivity C-reactive protein and total antioxidant in renal transplant recipients with rennin–angiotensin system polymorphisms. Transplant Proc 40: 16–21.
5. Bahadir O. Uzunlulu M. Oguz A. Bahadir M.A. (2007) Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome. Hypertens Res 30: 49–53.
6. Bautista L.E. Atwood J.E. O'Malley P.G. Taylor A.J. (2004) Association between C-reactive protein and hypertension in healthy middle-aged men and women. Coron Artery Dis 15: 331–336.
7. Black S. Kushner I. Samols D. (2004) C-reactive protein. J Biol Chem 279: 48487–48490.
8. Bloch M.J. (2007) Do angiotensin receptor antagonists decrease hsCRP independent of blood pressure – and does it matter? J Clin Hypertens (Greenwich) 9: 57–59.
9. Cesari M. Penninx B.W. Newman A.B. Kritchevsky S.B. Nicklas B.J. Sutton-Tyrrell K. et al (2003) Inflammatory markers and onset of cardiovascular events: results from the Health ABC Study. Circulation 108: 2317–2322.
10. Christensen M.K. Olsen M.H. Wachtell K. Tuxen C. Fossum E. Bang L.E. et al (2006) Does long-term losartan- vs atenolol-based antihypertensive treatment influence collagen markers differently in hypertensive patients? A LIFE substudy. Blood Press 15: 198–206.
11. Cooper-Dehoff R.M. Pacanowski M.A. Pepine C.J. (2009) Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum. J Am Coll Cardiol 53: S28–S34.
12. Dauphinot V. Roche F. Kossovsky M.P. Schott A.M. Pichot V. Gaspoz J.M. et al (2009) C-reactive protein implications in new-onset hypertension in a healthy population initially aged 65 years: the Proof study. J Hypertens 27: 736–743.
13. Davies J. Carr E. Band M. Morris A. Struthers A. (2005) Do losartan and atenolol have differential effects on BNP and central haemodynamic parameters? J Renin Angiotensin Aldosterone Syst 6: 151–153.
14. de Luis D.A. Conde R. Gonzalez-Sagrado M. Aller R. Izaola O. Duenas A. et al (2010) Effects of telmisartan vs olmesartan on metabolic parameters, insulin resistance and adipocytokines in hypertensive obese patients. Nutr Hosp 25: 275–279.
15. de Vinuesa S.G. Goicoechea M. Kanter J. Puerta M. Cachofeiro V. Lahera V. et al (2006) Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade. J Am Soc Nephrol 17: S206–S212.
16. Deary A.J. Schumann A.L. Murfet H. Haydock S. Foo R.S. Brown M.J. (2002) Influence of drugs and gender on the arterial pulse wave and natriuretic peptide secretion in untreated patients with essential hypertension. Clin Sci (Lond) 103: 493–499.
17. Del Fiorentino A. Cianchetti S. Celi A. Dell'omo G. Pedrinelli R. (2009) The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man. Vasc Health Risk Manag 5: 233–242.
18. Derosa G. Fogari E. D'Angelo A. Cicero A.F. Salvadeo S.A. Ragonesi P.D. et al (2007) Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J Clin Pharm Ther 32: 261–268.
19. Derosa G. Maffioli P. Salvadeo S.A. Ferrari I. Gravina A. Mereu R. et al (2010) Candesartan effect on inflammation in hypertension. Hypertens Res Clin Experiment 33: 209–213.
20. Diez J. Querejeta R. López B. Gonzalez A. Larman M. Martinez Ubago J.L. (2002) Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105: 2512–2517.
21. Doi M. Miyoshi T. Hirohata S. Kamikawa S. Usui S. Kaji Y. et al (2010) Combination therapy of calcium channel blocker and angiotensin II receptor blocker reduces augmentation index in hypertensive patients. Am J Med Sci 339: 433–439.
22. Dziadzio M. Denton C.P. Smith R. Howell K. Blann A. Bowers E. et al (1999) Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 42: 2646–2655.
23. Enjoji M. Kotoh K. Kato M. Higuchi N. Kohjima M. Nakashima M. et al (2008) Therapeutic effect of ARBs on insulin resistance and liver injury in patients with NAFLD and chronic Hepatitis C: a pilot study. Int J Mol Med 22: 521–527.
24. Ferguson J.M. Minas J. Siapantas S. Komesaroff P.A. Sudhir K. (2008) Effects of a fixed-dose ACE inhibitor-diuretic combination on ambulatory blood pressure and arterial properties in isolated systolic hypertension. J Cardiovasc Pharmacol 51: 590–595.
25. Fogari R. Derosa G. Ferrari I. Corradi L. Zoppi A. Lazzari P. et al (2008) Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. Am J Hypertens 21: 1034–1039.
26. Fogari R. Preti P. Zoppi A. Lazzari P. Corradi L. Fogari E. et al (2006) Effects of amlodipine–atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. Eur J Clin Pharmacol 62: 817–822.
27. Fujita M. Okuda H. Tsukamoto O. Asano Y. Hirata Y.L. Kim J. et al (2006) Blockade of angiotensin II receptors reduces the expression of receptors for advanced glycation end products in human endothelial cells. Arterioscler Thromb Vasc Biol 26: e138–e142.
28. Futai R. Ito T. Kawanishi Y. Terasaki F. Kitaura Y. (2009) Olmesartan ameliorates myocardial function independent of blood pressure control in patients with mild-to-moderate hypertension. Heart Vessels 24: 294–300.
29. Ge C.J. Lu S.Z. Chen Y.D. Wu X.F. Hu S.J. Ji Y. (2008) Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. Heart Vessels 23: 91–95.
30. Genest J. (2004) Preventive cardiology: move over low density lipoprotein cholesterol, hello C-reactive protein? Can J Cardiol 20(Suppl B): 89B–92B.
31. Guo L.L. Pan Y. Jin H.M. (2009) Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. Nephrol Dial Transplant 24: 1876–1883.
32. Igarashi M. Hirata A. Kadomoto Y. Tominaga M. (2006) Dual blockade of angiotensin II with enalapril and losartan reduces proteinuria in hypertensive patients with type 2 diabetes. Endocr J 53: 493–501.
33. Ishikawa J. Kario K. Matsui Y. Shibasaki S. Morinari M. Kaneda R. et al (2005) Collagen metabolism in extracellular matrix may be involved in arterial stiffness in older hypertensive patients with leftventricular hypertrophy. Hypertens Res 28: 995–1001.
34. Ishimitsu T. Kobayashi T. Honda T. Takahashi M. Minami J. Ohta S. et al (2005) Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients. Hypertens Res 28: 351–359.
35. Ishimitsu T. Numabe A. Masuda T. Akabane T. Okamura A. Minami J. et al (2009) Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension. Hypertens Res Clin Experiment 32: 962–968.
36. Jin H.M. Pan Y. (2007) Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy. Nephrol Dial Transplant 22: 1943–1949.
37. Karalliedde J. Smith A. Deangelis L. Mirenda V. Kandra A. Botha J. et al (2008) Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension 51: 1617–1623.
38. Karthikeyan V.J. Lip G.Y. (2007) Antihypertensive treatment, adiponectin and cardiovascular risk. J Hum Hypertens 21: 8–11.
39. Kawamura M. Ito H. Onuki T. Miyoshi F. Watanabe N. Asano T. et al (2010) Candesartan decreases type III procollagen-N-peptide levels and inflammatory marker levels and maintains sinus rhythm in patients with atrial fibrillation. J Cardiovasc Pharmacol 55: 511–517.
40. Kim S.H. Chung W.Y. Zo J.H. Kim M.A. Chang H.J. Cho Y.S. et al (2009) Efficacy and tolerability of two formulations of ramipril in Korean adults with mild to moderate essential hypertension: an 8-week, multicenter, prospective, randomized, open-label, parallel-group noninferiority trial. Clin Ther 31: 988–998.
41. Kintscher U. Bramlage P. Paar W.D. Thoenes M. Unger T. (2007) Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the treat to target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol 6: 12–13.
42. Kniepeiss D. Wagner D. Wirnsberger G. Roller R.E. Wasler A. Iberer F. et al (2010) Serum cystatin C is an easy to obtain biomarker for the onset of renal impairment in heart transplant recipients. J Thorac Cardiovasc Surg 140: 688–693.
43. Koh K.K. Han S.H. Ahn J.Y. Chung W.J. Lee Y. Shin E.K. (2009) Amlodipine improves endothelial function and metabolic parameters in patients with hypertension. Int J Cardiol 133: 23–31.
44. Koh K.K. Quon M.J. Han S.H. Chung W.J. Ahn J.Y. Seo Y.H. et al (2004) Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 110: 3687–3692.
45. Koh K.K. Quon M.J. Han S.H. Lee Y. Kim S.J. Koh Y. et al (2010) Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Int J Cardiol 140: 73–81.
46. Komoda H. Inoue T. Node K. (2010) Anti-inflammatory properties of azelnidipine, a dihydropyridine-based calcium channel blocker. Clin Exp Hypertens 32: 121–128.
47. Krikken J.A. Waanders F. Dallinga-Thie G.M. Dikkeschei L.D. Vogt L. Navis G.J. et al (2009) Antiproteinuric therapy decreases LDL-cholesterol as well as HDL-cholesterol in non-diabetic proteinuric patients: relationships with cholesteryl ester transfer protein mass and adiponectin. Expert Opin Ther Targets 13: 497–504.
48. Krusinova E. Klementova M. Kopecky J. Wohl P. Kazdova L. Mlejnek P. et al (2007) Effect of acute hyperinsulinaemia with and without angiotensin II type 1 receptor blockade on resistin and adiponectin concentrations and expressions in healthy subjects. Eur J Endocrinol 157: 443–449.
49. Lambers Heerspink H.J. Perkovic V. de Zeeuw D. (2009) Renal and cardio-protective effects of direct renin inhibition: a systematic literature review. J Hypertens 27: 2321–2331.
50. Laterza O.F. Price C.P. Scott M.G. (2002) Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 48: 699–707.
51. Laviades C. Varo N. Diez J. (2000) Transforming growth factor beta in hypertensives with cardiorenal damage. Hypertension 36: 517–522.
52. Lloyd-Jones D. Adams R.J. Brown T.M. Carnethon M. Dai S. de Simone G. et al (2010) Heart disease and stroke statistics – 2010 update: a report from the American Heart Association. Circulation 121: e46–e215.
53. López B. Gonzalez A. Querejeta R. Diez J. (2005) The use of collagen-derived serum peptides for the clinical assessment of hypertensive heart disease. J Hypertens 23: 1445–1451.
54. López B. Querejeta R. Varo N. Gonzalez A. Larman M. Martinez Ubago J.L. et al (2001) Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 104: 286–291.
55. Lorenzen J.M. Neunhoffer H. David S. Kielstein J.T. Haller H. Fliser D. (2010) Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension – results from the EUTOPIA trial. Atherosclerosis 209: 184–188.
56. Luc G. Bard J.M. Juhan-Vague I. Ferrieres J. Evans A. Amouyel P. et al (2003) C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the Prime study. Arterioscler Thromb Vasc Biol 23: 1255–1261.
57. Maisel A.S. (2009) Cardiovascular and renal surrogate markers in the clinical management of hypertension. Cardiovasc Drugs Ther 23: 317–326.
58. Makita S. Abiko A. Naganuma Y. Moriai Y. Nakamura M. (2007) Potential effects of angiotensin II receptor blockers on glucose tolerance and adiponectin levels in hypertensive patients. Cardiovasc Drugs Ther 21: 317–318.
59. Martinez Martin F.J. (2009) Manidipine in hypertensive patients with metabolic syndrome: the Marimba study. Expert Rev Cardiovasc Ther 7: 863–869.
60. Martínez-Martín F.J. Rodríguez Rosas H. Peiro-Martinez I. Soriano-Perera P. Pedrianes-Martín P. Comi-Díaz C. (2010) Olmesartan / amlodipine vs olmesartan / hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. J Hum Hypertens 1–8.
61. Masajtis-Zagajewska A. Majer J. Nowicki M. (2010) Effect of moxonidine and amlodipine on serum Ykl-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients – a randomized, crossover trial. Hypertens Res Clin Experiment 33: 348–353.
62. Massey D. (2004) Commentary: Clinical diagnostic use of cystatin C. J Clin Lab Anal 18: 55–60.
63. Matsui Y. Eguchi K. O'Rourke M.F. Ishikawa J. Miyashita H. Shimada K. et al (2009) Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension 54: 716–723.
64. Matsumoto S. Takebayashi K. Aso Y. (2006) The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metabolism 55: 1645–1652.
65. Matthews D.R. Hosker J.P. Rudenski A.S. Naylor B.A. Treacher D.F. Turner R.C. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419.
66. Mena C. Robles N.R. de Prado J.M. Gallego F.G. Cidoncha A. (2010) Cystatin C and blood pressure: results of 24 h ambulatory blood pressure monitoring. Eur J Intern Med 21: 185–190.
67. Merchant N. Rahman S.T. Ferdinand K.C. Haque T. Umpierrez G.E. Khan B.V. (2010) Effects of Nebivolol in Obese African Americans with Hypertension (NOAAH): markers of inflammation and obesity in response to exercise-induced stress. J Hum Hypertens 25: 196–202.
68. Montecucco F. Mach F. (2009) Update on therapeutic strategies to increase adiponectin function and secretion in metabolic syndrome. Diabetes Obes Metab 11: 445–454.
69. Morgan T. Lauri J. Bertram D. Anderson A. (2004) Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 17: 118–123.
70. Moriuchi A. Yamasaki H. Shimamura M. Kita A. Kuwahara H. Fujishima K. et al (2007) Induction of human adiponectin gene transcription by telmisartan, angiotensin receptor blocker, independently on PPAR-gamma activation. Biochem Biophys Res Comm 356: 1024–1030.
71. Muller-Brunotte R. Kahan T. López B. Edner M. Gonzalez A. Diez J. et al (2007) Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA). J Hypertens 25: 1958–1966.
72. Nagamia S. Pandian A. Cheema F. Natarajan R. Khan Q.A. Patel A.D. et al (2007) The role of quinapril in the presence of a weight loss regimen: endothelial function and markers of obesity in patients with the metabolic syndrome. Prev Cardiol 10: 204–209.
73. Navalkar S. Parthasarathy S. Santanam N. Khan B.V. (2001) Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol 37: 440–444.
74. Neal D.A. Brown M.J. Wilkinson I.B. Byrne C.D. Alexander G.J. (2004) Hemodynamic effects of amlodipine, bisoprolol, and lisinopril in hypertensive patients after liver transplantation. Transplantation 77: 748–750.
75. Negro R. Formoso G. Hassan H. (2006) The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients. J Endocrinol Invest 29: 957–961.
76. Negro R. Hassan H. (2006) The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients. J Renin Angiotensin Aldosterone Syst 7: 243–246.
77. Nelson M.R. Stepanek J. Cevette M. Covalciuc M. Hurst R.T. Tajik A.J. (2010) Noninvasive measurement of central vascular pressures with arterial tonometry: clinical revival of the pulse pressure waveform? Mayo Clin Proc 85: 460–472.
78. Nielsen S. Lihn A.S. Stergaard T. Mogensen C.E. Schmitz O. (2004) Increased plasma adiponectin in losartan-treated type 1 diabetic patients. A mediator of improved insulin sensitivity? Horm Metab Res 36: 194–196.
79. Nishimura H. Sanaka T. Tanihata Y. Naito T. Higuchi C. Otsuka K. (2008) Losartan elevates the serum high-molecular weight-adiponectin isoform and concurrently improves insulin sensitivity in patients with impaired glucose metabolism. Hypertens Res 31: 1611–1618.
80. Novo S. Lunetta M. Evola S. Novo G. (2009) Role of ARBs in the blood hypertension therapy and prevention of cardiovascular events. Current Drug Targets 10: 20–25.
81. Packard R.R. Libby P. (2008) Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 54: 24–38.
82. Pai J.K. Pischon T. Ma J. Manson J.E. Hankinson S.E. Joshipura K. et al (2004) Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 351: 2599–2610.
83. Paoletti R. Gotto A.M. Jr. Hajjar D.P. (2004) Inflammation in atherosclerosis and implications for therapy. Circulation 109: 1–7.
84. Park H. Hasegawa G. Obayashi H. Fujinami A. Ohta M. Hara H. et al (2006) Relationship between insulin resistance and inflammatory markers and anti-inflammatory effect of losartan in patients with type 2 diabetes and hypertension. Clin Chim Acta 374: 129–134.
85. Persson F. Rossing P. Hovind P. Stehouwer C.D. Schalkwijk C. Tarnow L. et al (2006) Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. Diabetes 55: 3550–3555.
86. Piecha G. Adamczak M. Chudek J. Wiecek A. (2007) Indapamide decreases plasma adiponectin concentration in patients with essential hypertension. Kidney Blood Press Res 30: 187–194.
87. Polonia J. Barbosa L. Silva J.A. Maldonado J. (2003) Different influences on central and peripheral pulse pressure, aortic wave reflections and pulse wave velocity of three different types of antihypertensive drugs. Rev Port Cardiol 22: 1485–1492.
88. Prats M. Font R. Bardaji A. Gutierrez C. Lalana M. Vilanova A. et al (2010) Cystatin C and cardiac hypertrophy in primary hypertension. Blood Press 19: 20–25.
89. Ridker P.M. Danielson E. Rifai N. Glynn R.J. (2006) Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-Marc trial. Hypertension 48: 73–79.
90. Ruilope L.M. Malacco E. Khder Y. Kandra A. Bonner G. Heintz D. (2005) Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther 27: 578–587.
91. Savoia C. Schiffrin E.L. (2007) Reduction of C-reactive protein and the use of anti-hypertensives. Vasc Health Risk Manag 3: 975–983.
92. Scaglione R. Argano C. Di Chiara T. Parrinello G. Colomba D. Avellone G. et al (2007) Effect of dual blockade of renin-angiotensin system on TGF-beta1 and left ventricular structure and function in hypertensive patients. J Hum Hypertens 21: 307–315.
93. Schepke M. Werner E. Biecker E. Schiedermaier P. Heller J. Neef M. et al (2001) Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology 121: 389–395.
94. Schulz R. Heusch G. (2009) Tumor necrosis factor-alpha and its receptors 1 and 2: yin and yang in myocardial infarction? Circulation 119: 1355–1357.
95. Shargorodsky M. Boaz M. Goldberg Y. Matas Z. Gavish D. Fux A. et al (2009) Adiponectin and vascular properties in obese patients: is it a novel biomarker of early atherosclerosis? Int J Obes (Lond) 33: 553–558.
96. Shibasaki Y. Nishiue T. Masaki H. Tamura K. Matsumoto N. Mori Y. et al (2005) Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. Hypertens Res 28: 787–795.
97. Shurtz-Swirski R. Farah R. Sela S. Shapiro G. Klempef R. Snitkovski T. et al (2006) [The effect of calcium channel blocker lercanidipine on low-grade inflammation parameters in essential hypertension patients]. Harefuah 145: 895–899, 942.
98. Sola S. Mir M.Q. Cheema F.A. Khan-Merchant N. Menon R.G. Parthasarathy S. et al (2005) Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation 111: 343–348.
99. Sugihara M. Miura S. Takamiya Y. Kiya Y. Arimura T. Iwata A. et al (2009) Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation. Hypertens Res Clin Experiment 32: 625–630.
100. Szmigielski C. Raczkowska M. Styczynski G. Pruszczyk P. Gaciong Z. (2006) Metabolism of collagen is altered in hypertensives with increased intima media thickness. Blood Press 15: 157–163.
101. Tomiyama H. Yambe M. Yamada J. Motobe K. Koji Y. Yoshida M. et al (2007) Discrepancy between improvement of insulin sensitivity and that of arterial endothelial function in patients receiving antihypertensive medication. J Hypertens 25: 883–889.
102. Tylicki L. Biedunkiewicz B. Chamienia A. Wojnarowski K. Zdrojewski Z. Aleksandrowicz E. et al (2007) Renal allograft protection with angiotensin II type 1 receptor antagonists. Am J Transplant 7: 243–248.
103. Usui I. Fujisaka S. Yamazaki K. Takano A. Murakami S. Yamazaki Y. et al (2007) Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients. Diabetes Res Clin Pract 77: 210–214.
104. Vasan R.S. (2006) Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 113: 2335–2362.
105. Wang X. Keith J.C. Jr. Struthers A.D. Feuerstein G.Z. (2008) Assessment of arterial stiffness, a translational medicine biomarker system for evaluation of vascular risk. Cardiovasc Ther 26: 214–223.
106. Watanabe S. Okura T. Kurata M. Irita J. Manabe S. Miyoshi K. et al (2006 a) Valsartan reduces serum cystatin C and the renal vascular resistance in patients with essential hypertension. Clin Exp Hypertens 28: 451–461.
107. Watanabe S. Okura T. Kurata M. Irita J. Manabe S. Miyoshi K. et al (2006 b) The effect of losartan and amlodipine on serum adiponectin in Japanese adults with essential hypertension. Clin Ther 28: 1677–1685.
108. Williams B. Lacy P.S. (2009) Central aortic pressure and clinical outcomes. J Hypertens 27: 1123–1125.
109. Williams B. Lacy P.S. Thom S.M. Cruickshank K. Stanton A. Collier D. et al (2006) Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113: 1213–1225.
110. Yilmaz M.I. Sonmez A. Caglar K. Celik T. Yenicesu M. Eyileten T. et al (2007) Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton) 12: 147–153.
111. Ylinen E.A. Ala-Houhala M. Harmoinen A.P. Knip M. (1999) Cystatin C as a marker for glomerular filtration rate in pediatric patients. Pediatr Nephrol 13: 506–509.
112. Zandbergen A.A. Lamberts S.W. Janssen J.A. Bootsma A.H. (2006) Short-term administration of an angiotensin-receptor antagonist in patients with impaired fasting glucose improves insulin Sensitivity and increases free IGF-I. Eur J Endocrinol 155: 293–296.